Abstract Acquired resistance to endocrine therapies presents a major obstacle to the successful treatment of breast cancer patients. Previously, we have shown that acquisition of resistance to tamoxifen in breast cancer cells is accompanied by an elevation in Src kinase activity which promotes an aggressive, invasive phenotype in vitro. Here, we have explored the potential therapeutic effects of combining Src inhibition with anti-oestrogen treatment on the development of endocrine insensitivity in breast cancer cells. Treatment of MCF7 and T47D cells with tamoxifen alone resulted in an initial growth inhibitory phase followed by the eventual development of tamoxifen resistance together with an elevation of Src kinase activity, which was central to their increased invasive capacity. Chronic exposure of both cell types to the Src inhibitor, AZD0530, as a monotherapy resulted in outgrowth of AZD0530-resistant cells, in which Src kinase activity remained suppressed as did their in vitro invasive nature. Treatment of both MCF7 and T47D cells with AZD0530 in combination with tamoxifen resulted in a reduction of Src activity together with inhibition of focal adhesion kinase phosphorylation and a complete abrogation of their in vitro invasive behaviour. Furthermore, combination therapy significantly suppressed expression of cyclinD1 and c-myc and prevented cell proliferation and the subsequent emergence of a resistant phenotype, with total cell loss occurring by 12
Introduction
Steroid hormones are central in directing the growth and development of oestrogen receptor (ER) positive breast cancers; as such, endocrine therapies which seek to perturb the steroid hormone environment of the tumour cells can promote extensive remissions in established disease and provide significant benefits in terms of patient survival [1, 2] . However, despite the undoubted improvements brought by endocrine therapies, in practice their benefits are limited by the capacity of a significant proportion of breast cancer patients that show an initial positive response to ultimately suffer a recurrence due to acquired antioestrogen resistance [3] [4] [5] [6] . In these patients, relapse on such therapies clinically presents as local and/or regional recurrences, frequently with distant metastases [7] and the outlook for these patients is poor. Recent in vitro studies have demonstrated that chronic exposure of breast cancer cells to tamoxifen ultimately results in the acquisition of tamoxifen resistance [8, 9] which is accompanied by the gain of aggressive, invasive characteristics [10, 11] .
Overexpression of the non-receptor tyrosine kinase, Src, and/or an increase in its kinase activity has been associated with the development and progression of a number of human malignancies including breast cancer [12, 13] where it has been implicated in metastatic progression [14] . Interestingly, it has recently been reported that expression of activated Src is associated with a reduced recurrencefree survival in ductal carcinoma in situ [15] . Steroidinduced cellular responses involve activation of Src and, although the molecular pathways involved in these responses have yet to be fully defined, can involve growth factor receptor signalling. For example, targeting of the Cterminal region of the ER to the membrane of ER-negative breast cancer cells results in oestrogen-stimulated, c-Srcdependent responses including activation of the epidermal growth factor receptor (EGFR) [16] . Furthermore, oestrogen stimulation results in the recruitment and activation of Src leading to activation of Shc, MEK/MAPK, and PI3K/ PKB [17] . Significantly, we have recently identified that Src kinase activity is significantly elevated in tamoxifenresistant breast cancer cells, where it promotes an aggressive, invasive phenotype [11] . A role for Src kinase in acquired endocrine resistance has also been suggested by others, where it may contribute to cellular growth via regulation of Cas-mediated EGFR signalling [18] or through interplay with focal adhesion kinase (FAK) [19] .
Given the putative role of Src in acquired tamoxifen resistance, we hypothesised that targeting of Src alongside the ER would present a novel strategy to suppress the development of an aggressive endocrine-resistant phenotype. In this report, we demonstrate that combined targeting of the ER and Src kinase using tamoxifen and the novel Src inhibitor, AZD0530 [20] in two separate, ERpositive breast cancer cell lines, greatly enhances the growth inhibitory effects seen with either agent alone, preventing the development of acquired tamoxifen resistance.
Materials and methods

Cell culture
Tamoxifen-responsive MCF7 and T47D breast cancer cells were routinely cultured in home medium (RPMI medium supplemented with 5% foetal calf serum (FCS), 10 IU/ml penicillin, 10 lg/ml streptomycin, 2.5 lg/ml fungizone and 200 mM glutamine). Subsequent treatment of these cells was performed in experimental medium (phenol-red free RPMI containing 5% charcoal-stripped, steroid-depleted FCS with antibiotics and glutamine as above) supplemented with 10 -7 M tamoxifen (4-hydroxy tamoxifen), AZD0530 (0-1 lM) or both agents in combination as indicated. In all cases the tissue culture medium (±tamoxifen/AZD0530) was replaced every 3 days unless otherwise stated. Stock solutions of AZD0530 and tamoxifen were dissolved in DMSO and ethanol respectively prior to diluting in tissue culture medium. Corresponding DMSO/ethanol controls had no effect on the parameters analysed. Treatment of cells with AZD0530 alone produced similar results irrespective of whether cells were cultured in home medium or experimental medium.
Cell growth assays
Cells were grown for 10 days in the presence of tamoxifen (10 -7 M), AZD0530 (0-1 lM) or a combination of both agents. Changes in cell growth were then evaluated by means of trypsin dispersion and subsequent counting using a Coulter Counter. To determine the effects of chronic exposure to these agents on the growth of both cell lines, log-phase cell cultures were either grown in home medium with no treatments or exposed to tamoxifen ± AZD0530 (0-1 lM) in experimental medium with routine passaging once cell confluency had reached *80%. Each passage was subsequently recorded and plotted against time in culture to allow the comparison of the ability of these treatments to maintain their growth suppressive effects.
Measurement of apoptosis
Cells were harvested at various times during long-term culture and apoptotic events analysed using a Vybrant Apoptosis Assay (Molecular Probes, Eugene, OR, USA) as follows: harvested cells were washed and resuspended to 1 9 10 6 cells/ml in PBS prior to the addition of FITClabelled YO-PRO-1 (final concentration of 100 nM) and TRITC-labelled propidium iodide (final concentration of 1.5 nM) for 30 min at 4°C. Cells were immediately read on a FACScan flow cytometer. Negative controls consisted of cells alone without antibody. The mean fluorescence of a minimum of 1 9 10 4 cells was determined for each sample and the experiments were repeated 4 times, each time in duplicate. Data represents mean of three separate experiments, each performed in duplicate.
RT-PCR
Total RNA was extracted from MCF7 and T47D cells using Trizol reagent (Life Technologies) and converted to cDNA using random hexamers and Super-Script II reverse transcriptase (Invitrogen). cDNA was amplified using PCR primer pairs (MWG Biotech) specific for c-myc (Fwd:5 0 -ccaagctcgtctcagagaag-3 0 , Rev:5 0 -cagcaggatagtccttccga-3 0 ) and cyclin-D1 (Fwd:5 0 -ggatgctggaggtctgcgag-3 0 , Rev:5 0 -gagaggaagcgtgtgaggcg-3 0 ). All PCR reactions were performed as multiplex reactions with PCR primers specific for b-actin (Fwd:5 0 -ccttcctgggcatggagtcct-3 0 , Rev:5 0 -ggag caatgatcttgatctt-3 0 ) as an internal control. PCR was performed in a semi-quantitative manner using 25 cycles so that products were in the linear range of amplification. PCR products were separated on a 1.0% agarose gel, stained with ethidium bromide and visualized and photographed under ultraviolet light.
Measurement of cellular proliferation
Ki67 antigen was assessed in both cell types following treatment with tamoxifen ± AZD0530 using the MIB-1 anti-Ki67 antibody (Coulter Electronics, Luton, United Kingdom). Briefly, cells were grown and treated in petri dishes containing coverslips as indicated then washed and fixed in formal saline. Primary antibody (MIB-1) was applied to the coverslips after blocking with PBS/Tween and incubation performed for 60 min. After washing in PBS, the secondary antibody (Mouse Envision, DAKO UK Ltd., Ely, Cambridgeshire) was applied to the coverslips for 75 min. After further PBS washing, the chromogen (''SigmaFast'' DAB, Sigma, Poole, UK) was added to the cells for 10 min after which the coverslips were rinsed in distilled water. Samples were counterstained with 20% haematoxylin for 3 min and mounted for examination by light microscopy. Control coverslips (no primary antibody) were checked for non-specific binding before assessing staining intensity in the test samples. The percentage of Ki67-positive cells was estimated after counting at least 1,000 tumour cells.
Cell cycle analysis
Cells were cultured in the presence or absence of tamoxifen, AZD0530 or the combination for up to 8 weeks. For analysis of cell cycle, the cells were harvested by trypsinisation and resuspended at 10 -7 cells/ml before using the Cycletest Plus DNA reagent kit (Becton Dickinson) following the manufacturers instructions to produce uniform suspensions of single nuclei with DNA stained and suitable for reading on a FACScan Flow Cytometer (Becton Dickinson).
Cell migration and invasion assays Cells were exposed to tamoxifen ± AZD0530 for the times indicated in the figures prior to seeding onto fibronectincoated polycarbonate, microporous membranes (8 lm pore size) at 5 9 10 4 cells/membrane and allowed to migrate to the underside of the membrane for a period of 24 h. Migratory cells were fixed, stained with 0.5% crystal violet and counted. To determine the cells' invasive capacity, cells were seeded onto Matrigel-coated, porous membranes as described previously [10] . After 72 h culture, invaded cells were fixed, stained with DAPI and counted. Cell migration/invasion was quantified as the mean number of cells observed in each of eight random fields of view per sample, in duplicate with each experiment performed a minimum of three times.
Western blotting
Cells were harvested at 2 week intervals during their exposure to tamoxifen ± AZD0530 and lysates resolved by SDS-PAGE using 8% gels. Proteins were immobilised on nitrocellulose membranes and subsequently probed with phospho-specific antibodies that recognised the active forms of Src (Y419) and FAK (Y861, both from Biosource, Nivelles, Belgium). Tyrosine 419 in Src is a major positive-regulatory site, the phosphorylation of which increases Src activity and is widely used as a indicator of changes in Src activity both in vitro and in vivo (for example, see [21] . Although other tyrosine residues on FAK are phosphorylated in a Src-dependent manner, phosphorylation of FAK at Y861 was investigated as this is well known to regulate cancer cell migration and to be increased in metastatic breast cancer cells [22, 23] and thus may be important in regulating the effects of Src kinase in cancer cells. Repeat immunoprobings were performed using pan antibodies to determine total levels of these proteins and with b-actin to correct for loading. Western blots were then scanned to provide data for quantitation, with normalization against actin first. Each experiment was performed at least three times with representative gels shown.
Statistical analysis
Data was analysed using one-way ANOVA with post-hoc analysis in order to examine whether inclusion of AZD0530 (0.1 and 1 lM) significantly affected the observations obtained with tamoxifen alone. Significance was assumed at P \ 0.05.
Results
AZD0530 and tamoxifen together showed improved growth inhibitory effects compared with either agent alone
Treatment of both MCF7 and T47D cells with AZD0530 resulted in a dose-dependent inhibition of Src kinase activity, as shown by a decrease in phosphorylation of Src at Y419 (Fig. 1a) whilst having no effect on the level of Src protein in these cells. Despite both cell type having similar levels of Src kinase, T47D cells exhibited a small but nonsignificant decrease in sensitivity to the Src inhibitor. However, at the highest concentration of AZD0530 (1 lM), a corresponding inhibition of MAPK activity was also observed in both cell types. Treatment of cells with AZD0530 also resulted in a dose-dependent decrease in growth over a period of 10 days (Fig. 1b) . A modest suppression of cell growth was seen following culture with tamoxifen alone at this time point (Fig. 1c ) with T47D cells appearing more resistant to its growth inhibitory effects, as has been previously reported [24] . Importantly, when AZD0530 (1 lM) and tamoxifen were combined, maximal inhibition of cell growth over this time period was observed (Fig. 1c) . Analysis of the growth data by isobologram suggested that the combined effect of the two drugs was additive rather than synergistic (data not shown).
AZD0530 and tamoxifen prevent the emergence of tamoxifen resistance
Since prolonged exposure of breast cancer cell lines to antioestrogens ultimately results in acquired resistance [8, 9] , a process in which activated Src has been implicated [11, 18, 19] , we wished to determine whether inhibition of Src activity alongside tamoxifen treatment would delay or prevent the development of resistance. Chronic exposure of both MCF7 and T47D cells to tamoxifen resulted in the emergence of a resistant phenotype after an initial period of growth suppression, as demonstrated by the ability of these cells to regain their ability to grow in the presence of the antihormone (Fig. 2) . Interestingly, treatment with AZD0530 as a monotherapy also ultimately resulted in cells which were able to grow in the presence of this inhibitor, suggestive of further acquired drug resistance. Significantly, our data revealed that cells exposed to the combination of tamoxifen and AZD0530 did not grow but rather, a gradual loss of cells in culture was observed, with no viable cells visible by approximately 13 weeks (Fig. 2) .
Addition of AZD0530 to tamoxifen does not enhance apoptosis
We next investigated whether tamoxifen and AZD0530 combined increased cellular apoptosis. FACS analysis of cells cultured in the presence of tamoxifen ± AZD0530 revealed that combining these agents did not significantly increase the extent of apoptosis seen with either compound as a single agent. (Table 1 shows data from 1 and 8 weeks' continuous culture in the presence of these agents).
AZD0530 and tamoxifen in combination significantly suppress expression of the Ki67 antigen
Since an induction of apoptosis did not appear to play a significant role in AZD0530-induced prevention of acquired tamoxifen resistance, we next evaluated the proliferative capacity of MCF7 and T47D cells cultured in the presence of tamoxifen with and without AZD0530. Analysis of the Ki67 expression, a marker of cellular proliferation, revealed that the combination of AZD0530 and tamoxifen significantly inhibited cellular proliferation in both cell lines, an effect observable as early as 10 days post treatment (Fig. 3a-MCF7 cells, 3b-T47D cells). AZD0530 and tamoxifen together inhibit expression of key growth-regulatory genes
To address possible mechanisms underlying these proliferation changes, we analysed the expression of a number of cell proliferation regulators which may be modulated in a Src-dependent manner. In agreement with recent reports showing inhibition of key cell cycle control elements following Src inhibition [25] , we observed that suppression of Src activity in both MCF7 and T47D cells resulted in reduced expression of both cyclin-D1, necessary for the progression of cells from G1 to S phase, and c-Myc, a positive regulator of cellular proliferation [26] (Table 2) . Moreover, cells treated with the combination of the two agents had significantly lower levels of these genes at times [4 weeks ( Table 2) . Subsequent analysis of cell cycle progression in cells after 4 weeks treatment revealed that the combination of tamoxifen and AZD0530 together significantly reduced the number cells in S phase cell cycle in both cell lines compared with either treatment alone (Fig. 4) .
AZD0530 and tamoxifen together show improved effects against migration and invasion compared with either agent alone
We have previously reported that chronic exposure to tamoxifen results in the acquisition of a highly migratory and invasive phenotype in vitro in which Src activation plays a key role [10, 11] . We thus wished to determine whether inclusion of AZD0530 with tamoxifen during these long-term treatments could prevent this. The migratory and invasive capacity of both MCF7 and T47D cells was assessed every 2 weeks during long-term culture with tamoxifen ± AZD0530. After 10 weeks, the migratory and invasive capacity of MCF7 cells was seen to increase over their basal level (Fig. 5a) ; interestingly, analysis of lysates obtained from such cells revealed that levels of Src kinase were also elevated at this time point as was the activity of FAK, a Src-associated substrate involved in cellular migration [27] (Fig. 5b) . The migratory and invasive capacity of T47D cells at this time point was again elevated following culture with tamoxifen alone, although these levels did not reach significance until C12 weeks, at which time cells demonstrated greatly increased Src and FAK activity (Fig. 5b) . Inclusion of AZD0530 with tamoxifen significantly suppressed cell migration and invasion at all time points (Fig. 5a) , and consistently inhibited the activity of Src and FAK (Fig. 5b) . 
Discussion
Endocrine therapy is a major therapeutic option in the management of breast cancer. Tamoxifen is the most widely used anti-oestrogen, with approximately 50% of women having ER-positive breast disease benefiting from this treatment [28, 29] . However, acquisition of resistance to such therapies frequently arises and, in such cases, the identification of novel targets that promote a resistant phenotype may themselves prove useful targets through which the development of resistance and the associated tumour re-growth and spread may be delayed or prevented. We and others have recently identified a role for Src kinase in acquired endocrine resistance in vitro [11, 19] , where it may regulate both proliferative and invasive responses in such cells. Data is emerging which reveals Src kinase as a novel tumour target, where its inhibition is effective at suppressing proliferation and/or metastatic events in a wide range of tumour types including CML [30, 31] , colon tumours [32, 33] and pancreatic cancer [34, 35] . Further studies [36, 37] also provide compelling evidence that targeting Src may be of value in combination with existing chemotherapy to provide an augmented antitumour response. In breast cancer cells, Src is implicated as a key element in non-genomic, oestrogen-induced MAPK and MMP activation [16, 38, 39] and oestrogen-mediated cellular proliferation and cell-cycle progression [40, 41] . Interestingly, tamoxifen treatment itself has been reported to promote activation of intercellular signalling elements, including Src, resulting in cellular migration [42] and tamoxifen-mediated adhesion-dependent cell survival occurs through a Src-dependent process [43] . Thus, the ability to inhibit Src activity, alongside targeting of the ER with anti-oestrogens, may enhance the anti-tumour activity seen with each agent alone. Indeed, two recent studies provide compelling evidence to support such a hypothesis, demonstrating the short-term effectiveness of such combinational treatments in preventing the growth of MCF7 cells [25, 44] . However, it is currently unknown whether co-targeting both Src and the ER is effective in other ERpositive cell lines and whether such treatment regimens would be effective in circumventing the phenomena of acquired tamoxifen resistance that occurs following chronic exposure to this agent [8, 45, 46] .
Our data demonstrates that combining tamoxifen with the novel Src/Abl inhibitor, AZD0530 [20] , improves the growth-inhibitory response seen with each treatment alone. Moreover, whereas long-term treatment with each agent alone resulted in the acquisition of a resistant state as demonstrated by a regain in growth ability in the presence of the drug, cells exposed to the combination of tamoxifen and AZD0530 did not acquire resistance; rather, complete cell loss was observed following such treatments in two Table 2 RT-PCR analysis of proliferation-related gene expression was performed with subsequent densitometric analysis of PCR products , 1 lM) or the combination for 4 weeks. Cells were subsequently analysed for cell cycle phase using a flow cytometer. A significant reduction in cells in S phase was observed in cells cultured in the presence of tamoxifen plus AZD0530 combined. *P \ 0.05 vs. single agent treatment independent ER-positive cell lines (MCF7 and T47D). These data were achieved using clinically relevant concentrations of AZD0530 since data on the pharmacokinetics of AZD0530 suggest average plasma concentrations of 552 ng/ml [range 356-855 ng/ml] are achievable in humans using a single daily dose regimen [47] and are thus comparable with the concentrations used in this study (1 lM = 542 ng/ml).
Although inhibition of Src activity has previously been demonstrated to induce apoptosis in cancer cells through a variety of mechanisms including down regulation of Bcl-2 and Bcl-X L expression [48] , caspase activation [49] and decreased AKT phosphorylation [50] , we did not observed a significant increase in apoptotic cells following dual targeting of Src and ER. That apoptosis does not present a mechanism of cell loss induced by combination treatment Despite no evidence for a role of apoptosis, our data clearly demonstrates that combination treatment reduced the proliferative capacity of these cells, as revealed by a loss of expression of the Ki-67 cellular proliferation. Indeed, cell cultures treated with tamoxifen and AZD0530 combined were almost entirely Ki-67-negative after 4 weeks treatment. Although the ability of Src kinase inhibitors to suppress tumour cell growth are widely reported [51] [52] [53] , cells treated with either tamoxifen or AZD0530 alone still had a significant number of Ki-67-positive cells remaining at these time points. Our RT-PCR analysis suggests that these observations might be due to modulation of cyclin-D1 and c-myc, genes which play a central role in the control of cellular proliferation. Such data is not surprising given the reported interplay between Src and cell-cycle-associated genes [54, 55] ; indeed, it has been recently reported that pharmacological inhibition of Src activity in MCF7 cells results in suppression of both cMyc and cyclinD1 [19] . Our data here demonstrates that prolonged exposure to a Src inhibitor and tamoxifen results in even greater suppression of these elements and interestingly, cell cycle analysis revealed a significant reduction in the numbers of cells in S phase following combination treatment. Given that Ki67 positivity is significantly correlated with cells in S phase [56, 57] , these cell cycle observations confirm our Ki67 data and together these observations demonstrate that combined targeting of the ER and Src in ER-positive MCF7 and T47D cells results in a loss of proliferative response.
A significant impact of combining Src inhibition with tamoxifen was the ability to suppress the migratory and invasive characteristics of these cells. MCF7 cells are poorly invasive in vitro, whereas T47D cells have a higher intrinsic invasive capacity. However, despite these differences, the capacity of both cell types to migrate and invade in the absence of any exogenous stimulation in vitro is significantly enhanced following the long-term treatment with antihormones and the acquisition of an endocrineresistant state [11] and Fig. 5a ). Interestingly, T47D models of acquired resistance appeared generally less invasive than did MCF7 cells that were tamoxifen resistant. The acquisition of endocrine resistance is accompanied by altered expression and/or activation of growth factor signalling pathways (reviewed in [58] . However, it is likely that models of acquired resistance derived from different breast cancer cell lines (e.g. MCF7, T47D) will differ in the intrinsic expression of growth factor receptors/pathway components; i.e. the dominant signalling pathway in one model may not be the same for another. This can give rise to phenotypic differences between drug-resistant cells that may include their proliferative and invasive capacities. The observations that acquired resistance in vitro is accompanied by an enhanced invasive behaviour may have significant implications in vivo, where the development of aggressive characteristics, even in the absence of cellular proliferation, may favour cell dissemination and tumour spread. Interestingly, we observed that resistance was also acquired to AZD0530 monotherapy upon continued exposure, as was the case with tamoxifen. However, unlike tamoxifen resistant cells, AZD0530 resistant cells had only a modest invasive capacity further implicating Src activity as a key element in the acquisition of an aggressive cell phenotype. Despite Src activity remaining suppressed in AZD0530-resistant cells, little is known concerning the activity of other Src family kinases in such cells. Although AZD0530 is known to inhibit the Src family kinase Yes [20] , it remains to be determined whether there is a role for other members of the Src family in AZD0530-resistant cells and their contribution to their proliferative capacity.
Our data shows that the effect of combining AZD0530 and tamoxifen was to produce cells which were unable to migrate or invade in our in vitro assays. We and others have previously demonstrated that Src kinase promotes cellular invasion through a mechanism involving activation of FAK [11, 19, 59] . Importantly, dual treatment of both MCF7 and T47D cells, in addition to suppressing Src activity, also consistently suppressed the activity of the Src-associated molecule FAK a central component of the cells' migratory machinery. Such data may further reflect the potential benefit of combination drug regimens that involve Src inhibitors in suppressing characteristics of tumour behaviour involved in tumour spread.
In summary, these data suggest that integration of Src kinase inhibitors with current anti-oestrogen therapies may present a useful treatment regimen through which subsequent anti-oestrogen resistance development could be prevented.
